美国国立卫生研究院致力于加速COVID-19治疗的发展
美国国立卫生研究院致力于加速COVID-19治疗的发展
In an bid to help speed up the development of potential treatment options and a vaccine for COVID-19. the National Institutes of Health on Friday announced a new public-private research partnership.
为了帮助加速开发潜在的治疗方案和COVID-19疫苗，美国国立卫生研究院上周五宣布了一项新的公私合作研究伙伴计划。
The new initiative will be spearheaded by the NIH but also include the Food and Drug Administration, other parts of the federal government and a list of 16 companies that includes some of the biggest players in the pharmaceutical industry.
这项新计划将由美国国立卫生研究院(NIH)牵头，但也包括美国食品和药物管理局、联邦政府的其他部门，以及一份由16家公司组成的名单，其中包括一些最大的制药行业。
Among the companies participating in the effort are Pfizer, Johnson & Johnson and Merck.
参与这项工作的公司包括辉瑞、强生和默克。
"We need to have all hands on deck from every sector to speed up the process of identifying those treatments that are going to work and to get the vaccines also developed, tested, to make sure they're safe and effective in the maximum possible speed," said Dr. Francis Collins, director of the NIH, in an interview with NPR's All Things Considered.
美国国立卫生研究院院长弗朗西斯·柯林斯博士在接受美国国家公共广播公司《综合考虑》采访时说：“我们需要各个部门的全体人员，加快确定那些有效治疗方法的进程，并让疫苗也得到开发、测试，以确保它们以尽可能快的速度安全有效。”
The announcement comes after President Trump and public health officials on Thursday unveiled new guidelines for states to begin reopening the country.
周四，特朗普总统和公共卫生官员公布了重启美国的新指导方针。
Health experts say that in order to safely do that, there needs to be more testing, contact tracing and better drugs to treat COVID-19. Ultimately, for things to truly return to normal, an effective vaccine is needed.
卫生专家说，为了安全起见，需要进行更多的检测、追踪接触者以及更好的药物来治疗COVID-19.最终，要使一切真正恢复正常，就需要一种有效的疫苗。
Collins said there are already two vaccines in phase one trials, and behind that, a series of more than 40 other vaccines being developed as well. But he cautioned that the public should expect failures along the way.
柯林斯说，目前已经有两种疫苗处于第一阶段的试验阶段，在此之后，还有40多种其他疫苗也在研发中。但他警告说，公众应该预料到会有失败。
Collins also provided an update on testing of antiviral drug, remdesivir, and shared his thoughts on Dr. Anthony Fauci, the high-profile director of the National Institute of Allergy and Infectious Diseases.
柯林斯还介绍了抗病毒药物雷姆德西韦的最新测试情况，并分享了他对美国国家过敏和传染病研究所知名所长安东尼·福奇博士的看法。
Here are excerpts from the conversation.
以下是对话的节选。
There's a lot of buzz about an antiviral called remdesivir.
关于一种叫做雷姆德西韦的抗病毒药物有很多传言。
Remdesivir is certainly, I think, at the top of most people's hopeful list, but not yet proven. We're running a human trial with now 800 participants enrolled more quickly than expected. We will know, I think, in the next two to four weeks whether it worked or not.
我认为，雷姆德西韦肯定是大多数人希望的首选药物，但还没有得到证实。我们正在进行一项人体试验，现在有800名参与者加入，比预期的要快。我想，在接下来的两到四周内，我们将会知道它是否有效。
